Cell Line

Please note this product may be subject to fees, we invite you to contact your local office. PRAME TCR CD8⁺ NFAT-Luciferase Reporter Jurkat Cell Line was generated from T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by overexpression of human CD8 (NM_001768.6) and a PRAME (Preferentially Expressed Antigen in Melanoma)-directed TCR using lentiviral transduction (CD8a Lentivirus #78648 and PRAME-Specific TCR Lentivirus #78959). This PRAME TCR specifically recognizes an antigen PRAME peptide, amino acids peptide 425-433 (SLLQHLIGL).

Please note this product may be subject to fees, we invite you to contact your local office. The Vγ4Vδ1 TCR NFAT-Luciferase Reporter Jurkat Cell Line was generated from the T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (#78556) by overexpression of human Vγ4Vδ1 TCR using lentiviral transduction (with Vγ4Vδ1 TCR Lentivirus #78986). This cell line was functionally validated with a TCR Vδ1 agonist antibody.

Please note this product may be subject to fees, we invite you to contact your local office. The Transduction Control (EF1A Promoter) iPS Cell Pool is an iPS (induced pluripotent stem) cell pool that was generated via lentiviral transduction with Expression Negative Control Lentivirus (EF1A Promoter/Puromycin Resistance) (#82212-P). This cell pool can be used as control for Cas9 Expressing iPS Cell Pool (#78578).

Please note this product may be subject to fees, we invite you to contact your local office. CDH6 HEK293 Cell Line is a HEK293 stable cell line constitutively expressing human CDH6 (Cadherin-6/K-cadherin) protein (). This cell line was generated by lipid mediated transfection, followed by hygromycin selection, and limiting dilution. Individual clones were screened for CDH6 expression levels by flow cytometry and a high-level CDH6 expression clone was selected to generate this cell line.

Female. Gender: European. Age: 43 years. Ethnicity: Pleomorphic and multinucleated cells. Disease: Carcinoma. Please note this product may be subject to fees, we invite you to contact your local office.

Female. Age: Unspecified Please note this product may be subject to fees, we invite you to contact your local office.

Please note this product may be subject to fees, we invite you to contact your local office. The Transduction Control (Tet-On) iPS Cell Pool is an iPS (induced pluripotent stem) cell pool that was generated via lentiviral transduction with Expression Negative Control Lentivirus (Inducible Tet-On) (#82290). This cell pool can be used as control for Cas9 Inducible (Tet-On) iPS Cell Pool (BPS Bioscience #78845).

Please note this product may be subject to fees, we invite you to contact your local office. This cell line was generated by transducing the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) with lentiviruses (CD4 Lentivirus, Bioscience #78987) to overexpress human CD4 (NM_000616.5). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells that stably expressed firefly luciferase under the control of NFAT response elements. TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by both genomic sequencing and flow cytometry. Expression of CD4 in CD4⁺ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by flow cytometry. The cell line does not respond to anti-CD3 agonist antibodies, as opposed to the parental NFAT-Lucife

Please note this product may be subject to fees, we invite you to contact your local office. IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line is an engineered HEK293 cell line expressing firefly luciferase under the control of STAT3 response element, and human IL-23 receptor complex (IL12Rβ1 NM_005535.3 and IL23R NM_144701.3). With this cell line, IL-23 activity can be monitored by measuring luciferase activity. The functionality of the IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using a recombinant human interleukin 23 (human IL-23; p19 + p40), inhibition assays using the anti-IL-23 antibodies Ustekinumab and Guselkumab, as well as a Janus Kinase inhibitor, Ruxolitinib.